Dr Chung Kok

Adjunct Associate Professor Centre for Cancer Biology

email Chung.Kok@unisa.edu.au

Research Degree Supervisor

Research

Research focus

Cardiovascular Medicine and Haematology
Oncology and Carcinogenesis
Clinical Sciences
Genetics
Immunology

Research

Outputs

Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included.

Open access indicates that an output is open access.

Journal Articles

Year	Output
2025	Bayram Catak, F, Catak, MC, Babayeva, R, Toubia, J, Warnock, N I, Kok, CH, Cildir, G & Baris, S and 16 other authors 2025, 'Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease', Journal of Allergy and Clinical Immunology, vol. 155, no. 3, pp. 784-791. 3 5
2025	Bozkurt, C, Cildir, G, Aba, U, Erdogan, RK, Warnock, N I, Kok, CH & Erman, B and 20 other authors 2025, 'Comprehensive αβ T-Cell receptor repertoire analysis reveals a unique CD8 TCR landscape in DOCK8-deficient patients', Allergy: European Journal of Allergy and Clinical Immunology, online, pp. 1-12. Open access
2025	Kok, CH, Al-Kali, A, Thomas, D, He, R & Hiwase, DK and 17 other authors 2025, 'RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm', Blood Advances, vol. 9, no. 15, pp. 1-4.
2025	Toubia, J, Kusay, Y, Maqsood, M, Warnock, N I, Lawrence, DM, Bracken, CP, Gregory, PA, Kan, WL, Selth, LA, Conn, SJ, Lopez, AF, Branford, S, Scott, HS, Kok, CH, Goodall, GJ & Schreiber, AW 2025, 'TRanscriptome ANalysis of StratifiEd CohorTs (TRANSECT) enables automated assessment of global gene regulation linked to disparate expression in user defined genes and gene sets', NAR Genomics and Bioinformatics, vol. 7, no. 2, article no. lqaf041, pp. 1-13. Open access
2024	Cildir, G, Aba, U, Pehlivan, D, Tvorogov, D, Warnock, N I, Kok, CH, Tumes, DJ & Erman, B and 17 other authors 2024, 'Defective kinase activity of IKKα leads to combined immunodeficiency and disruption of immune tolerance in humans', Nature Communications, vol. 15, no. 1, pp. 1-18. Open access 1 1 9
2024	Hong, LE, Wechalekar, MD, Kutyna, M, Small, A, Scott, HS, Brown, A, Hahn, CN, Robinson, N, Branford, S, D'Andrea, RJ, Samaraweera, SE, Kok, CH & Hiwase, DK and 13 other authors 2024, 'IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation', Blood, vol. 143, no. 18, pp. 1873-1877. 8 9 33
2024	Kok, CH, Irani, Y, Clarson, J, Saunders, V, Dang, P, Shanmuganathan, N, Branford, S, Yeung, D, Yong, AS & Hughes, TP 2024, 'CD302 predicts achievement of deep molecular response in chronic myeloid leukemia patients treated with imatinib', Blood Neoplasia, vol. 1, no. 2, article no. 100014, pp. 1-11. Open access 1
2024	Kok, CH, Yeung, DT & Hiwase, DK 2024, 'Special Issue 'advances in Molecular Pathogenesis and targeted therapies for Myeloid Neoplasms'', International Journal of Molecular Sciences, vol. 25, no. 4, article no. 2056, pp. 1-5. Open access 1 1
2024	Wechalekar, MD, Zhao, LP, Kutyna, MM, Hong, LE, Li, J, Hung, K, Scott, HS, Brown, A, Hahn, CC, Kassahn, K, Ladon, D, Yeung, DT, Thomas, D, Patnaik, M, Proudman, S, Ades, L, Shah, M V, Kok, CH & Hiwase, DK 2024, 'Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features', Blood Cancer Journal, vol. 14, article no. 116, pp. 1-5. Open access 1 1
2023	Eşkazan, AE, Kok, CH, Yeung, D, Dalal, J & Tiribelli, M 2023, 'Editorial: advances in the treatment of chronic myeloid leukemia', Frontiers in Oncology, vol. 13, article no. 1166588, pp. 1-3. Open access 1
2023	Hiwase, D, Hahn, C, Tran, ENH, Chhetri, R, Wang, P, Kumar, S, Brown, A, Scott, H, Kok, CH & Shah, MV and 41 other authors 2023, 'TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype', Blood, vol. 141, no. 9, pp. 1087-1091. Open access 26 23 1
2023	Kok, CH, Saunders, VA, Dang, P, Shanmuganathan, N, White, D, Branford, S, Yeung, D & Hughes, TP 2023, 'Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib', Blood Cancer Journal, vol. 13, no. 1, pp. 1-9. Open access 2 1
2023	Kutyna, MM, Loone, S, Saunders, VA, White, DL, Kok, CH & Hiwase, DK 2023, 'Solute carrier family 29A1 mediates in vitro resistance to Azacitidine in Acute Myeloid Leukemia cell lines', International Journal of Molecular Sciences, vol. 24, no. 4, article no. 3553, pp. 1-14. Open access 3 3
2023	Shah, MV, Tran, ENH, Shah, S, Chhetri, R, Brown, AL, Scott, HS, Kumar, S, Hahn, CN, Kok, CH & Hiwase, DK and 12 other authors 2023, 'TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms', Blood Cancer Journal, vol. 13, no. 1, article no. 51, pp. 1-9. Open access 29 29 1
2023	Shanmuganathan, N, Wadham, C, Shahrin, NH, Feng, J, Thomson, D, Wang, P, Kok, CH, King, RM, Kenyon, RR, Lin, M, Ross, DM, Yeung, DT, Scott, HS, Schreiber, AW & Branford, S and 9 other authors 2023, 'Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention', Haematologica: The Hematology Journal, vol. 108, no. 9, pp. 2380-2395. Open access 18 16 15
2023	Sharplin, K, Proudman, W, Chhetri, R, Tran, ENH, Choong, J, Kutyna, M, Selby, P, Sapio, A, Friel, O, Khanna, S, Singhal, D, Damin, M, Ross, D, Yeung, D, Thomas, D, Kok, CH & Hiwase, D 2023, 'A personalized risk model for azacitidine outcome in myelodysplastic syndrome and other myeloid neoplasms identified by machine learning model utilizing real-world data', Cancers, vol. 15, no. 16, article no. 4019, pp. 1-14. Open access 3 3
2022	Shanmuganathan, N, Wadham, C, Thomson, D, Shahrin, NH, Vignaud, C, Obourn, V, Chaturvedi, S, Yang, F, Feng, J, Saunders, V, Kok, CH, Yeung, D, King, RM, Kenyon, RR, Lin, M, Wang, P, Scott, H, Hughes, T, Schreiber, AW & Branford, S 2022, 'RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia', Journal of Molecular Diagnostics, vol. 24, no. 7, pp. 803-822. Open access 8 6 3

External engagement & recognition

Collaborations

External engagement & recognition

Collaborations

Organisation	Country
Australasian Leukaemia and Lymphoma Group	AUSTRALIA
Central Adelaide Local Health Network Incorporated	AUSTRALIA
Flinders Medical Centre	AUSTRALIA
Flinders University	AUSTRALIA
Hacettepe University	TÜRKIYE
Istanbul University	TURKEY
Marmara University	TURKEY
Mayo Clinic	UNITED STATES
Novartis Institutes for Biomedical Research	UNITED STATES
Novartis Pharmaceuticals	UNITED STATES
Rainbow Babies & Children's Hospital	UNITED STATES
Royal Adelaide Hospital	AUSTRALIA
SA Pathology	AUSTRALIA
South Australian Health and Medical and Research Institute (SAHMRI)	AUSTRALIA
South Australian Health and Medical Institute	AUSTRALIA
University of Adelaide	AUSTRALIA
University of Paris	FRANCE
University of South Australia	AUSTRALIA
University of Udine	ITALY

Teaching & student supervision

Research degree supervision

Supervisions from 2010 shown

Thesis title	Student status
Enhanced bioinformatics for improved risk stratification and outcome prediction in chronic myeloid leukaemia (CML)	Current

more less

Dr Chung Kok

About me

About me

Centre for Cancer Biology

About me

Professional Associations

Research

Research focus

Projects

Outputs

Journal Articles

External engagement & recognition

Collaborations

Collaborations

Teaching & student supervision

Courses and programs

Research degree supervision

Gallery